The nature of the novel coronavirus has enabled the global medical community to create a research network, and adaptive trial designs are facilitating the study of multiple interventions at once against a single, shared control arm, write Takeda President of Research and Development Andy Plump and Amgen Executive Vice President of R&D David Reese. New analytic tools from the Bill and Melinda Gates Foundation have given researchers a look at summary-level statistics with only a 7-day lag, and TransCelerate's data sharing platform opened access to patient-level information from COVID-19 trials.
SARS-CoV-2 brings research community together
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.